The London Life Sciences team advised Adcendo on the closing of an oversubscribed $135 million Series B financing round.
The financing round was led by TCGX, with participation from new investors TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, as well as all existing investors, RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital.
Adcendo ApS is a clinical-stage biotechnology company developing breakthrough antibody-drug conjugates, or ADCs, for the treatment of underserved cancers. Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept.
The Goodwin deal team consisted of Sophie McGrath, Graham Defries, Lucy Thomas, Matthew Lee, Matthew Shelley, George Fagan, Harriet Worthington and Martina Kobal.
For more details on the financing, please see here.